Compare Oruka Therapeutics Inc. Common Stock (ORKA) vs Permian Resources Corporation Class A Common Stock (PR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oruka Therapeutics Inc. Common Stock vs Permian Resources Corporation Class A Common Stock — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B), while Permian Resources Corporation Class A Common Stock trades at $24.06 (market cap $20.32B). The key difference: Permian Resources Corporation Class A Common Stock is far larger — about 3.9× Oruka Therapeutics Inc. Common Stock's market cap, and Permian Resources Corporation Class A Common Stock pays a 2.6% dividend while Oruka Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and Permian Resources Corporation Class A Common Stock for 5 Days on average.
| ORKA | PR | |
|---|---|---|
Market Cap | $5.18B | $20.32B |
Volume | 490,798 | 10,979,775 |
Sector | Health | Energy |
52-Week High | $113.08 | $24.49 |
52-Week Low | $26.19 | $12.09 |
Typical Hold Time | 0 Days | 5 Days |
Enterprise Value | $4.31B | $23.32B |
Dividend Yield | — | 2.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Permian Resources (PR) trades at $24.26, up 3.68% on the day and near its 52-week high, with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with $5.07B revenue, 21.52% net income margin, and attractive valuation metrics including a P/E of 15.65 and EV/EBITDA of 5.83. Recent earnings show mixed results with Q2 2026 beating expectations by 59% while Q1 2026 missed estimates.
The outlook remains positive with 90% analyst buy ratings and $27.00 consensus price target representing 11% upside. Key opportunities include disciplined acquisition strategy and raised 2026 guidance, while risks involve oil price volatility and execution of capital spending plans. The stock offers growth potential but requires monitoring of quarterly execution consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →About Permian Resources Corporation Class A Common Stock
Permian Resources explores for and produces oil and natural gas in the Permian Basin. Its operations are concentrated in the Delaware Basin of West Texas and New Mexico.
Read more on PR →
